Digital breast tomosynthesis mammography unit HESTIA

Launched ‘HESTIA’ with DBT function. Obtained official certification for manufacturing and sales by the Ministry of Food and Drug Safety. Reduced dependence on foreign equipment and succeeded in localizing equipment. Genoray (CEO, Byung-Uk Park), a global imaging diagnostic medical device company, announced on the 10th that it has obtained DBT breast cancer diagnosis system manufacturing and sales certification from the Ministry of Food and Drug Safety (MFDS) for the first time in Korea. Genoray is planning to showcase the DBT breast cancer diagnosis system 'HESTIA' at the '36th International Medical Equipment & Hospital Equipment Show (KIMES2021)'. DBT stands for Digital Breast Tomosynthesis, and if this technology is used, unlike conventional 2D equipment, it is possible to observe a tomography image of the breast, enabling a much more precise breast cancer diagnosis. In addition, by increasing the breast cancer diagnosis efficiency by more than 30%, it is possible to optimize the diagnosis of microcalcifications and tumors of many dense breasts in Asian women, including Korea. In the domestic market, there is no domestic equipment that can compete with foreign equipment of the same kind, so it has relied only on expensive foreign equipment. With the release of 'HESTIA' this time, Genoray can enter the treatment market as well as hospitals, clinics, and examination centers, which were considering introduction due to expensive equipment prices and maintenance costs.